Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).

The Impact of Difficult to Treat Sites on Biological Treatment Response in Patients With Moderate-to-Severe Plaque Psoriasis

This study is to evaluate available local data in Iraq patients with moderate-to-severe plaque psoriasis on Enbrel treatment with regards to efficacy, treatment for PsO who have difficult to treat sites at presentation.

Inclusion Criteria:

• Moderate-to-severe plaque psoriasis patients whom have been receiving etanercept for at least 1 year duration.
• Have difficult to treat sites at presentation.
• Age ≥18 years.
• No history of using other biological treatments, other than etanercept for the treatment of moderate-to-severe PsO.

Exclusion Criteria:

• Etanercept use for treatment of moderate-to-severe PsO less than 1 year duration.
• Previous use of another biological treatment for treatment of moderate-to-severe PsO.